Deconstructing Exceptional Responses to Immune Checkpoint Inhibition in Recurrent or Metastatic Head and Neck Carcinoma: A Site-Specific Clinical-Biological Synthesis. (PubMed, Cancers (Basel)) - Sep 16, 2026 - " Landmark clinical data confirm durable survival benefits with frontline pembrolizumab-based regimens in selected PDL-1 positive populations compared to historical chemotherapy...Rather than a definitive or proven biological biomarker, the proposed blueprint represents an integrative hypothesis highlighting the complex interplay of baseline immune inflammation, genomic features, and viral drivers. Translating these observations into broader clinical benefit will require validated biomarker-driven personalization and rationally designed combination regimens."
Checkpoint inhibition • IO biomarker • Journal • Review • Epstein-Barr Virus Infections • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck
|
|
Francesco Chiari; Giovanni Motta; Giuseppe Tortoriello; Pasquale Capasso; Piero Giuseppe Meliante
|